Bunion Treatment Companies

Latest Bunion (Hallux Valgus) Treatment Companies Updates:

Stryker (US): Launched its new PROstep MIS Lapidus system in September 2023, offering a minimally invasive surgical option for bunion correction with reported benefits like lower recurrence rates, faster recovery, and reduced scar size compared to open procedures.

Johnson & Johnson (US): Received FDA clearance for its TriLEAP foot fixation device in August 2023, targeting both trauma and elective procedures like bunion surgery. J&J sees the growing bunion market as a future growth opportunity.

Treace Medical Concepts (US): Began limited US market release of three new complementary technologies for bunion and bunion-related procedures in September 2023, expanding its portfolio and potentially capturing a larger market share.

Intuitive Surgical (US): Saw a drop in bariatric procedure share due to competition from weight-loss drugs but predicts a rebound in 2024 as patients seeking surgery reschedule procedures. This could indirectly impact the Bunion Treatment Market as some patients opting for bariatric surgery might also require future bunion correction.

Medtronic (US): Downplayed the impact of weight-loss drugs on its bariatric surgery business, expecting negligible impact on its cardiovascular procedures and a potential increase in new patients considering surgery after a short-term drug phase. This could also indirectly impact the Bunion Treatment Market, similar to Intuitive Surgical.

List of Bunion (Hallux Valgus) Treatment Key companies in the market:

• Stryker Corporation (U.S.)


• Arthrex, Inc. (U.S.)


• Zimmer Biomet Holdings, Inc. (U.S.)


• Smith & Nephew plc (U.K.)


• Wright Medical Technology, Inc. (U.S.)


• Integra LifeSciences Holdings Corporation (U.S.)


• Tornier N.V. (Netherlands)


• Össur (Iceland), Acumed, LLC (U.S.)


• Extremity Medical, LLC (U.S.)


• De Puy Synthes (U.S.)


• Biomet, Inc. (U.S.